Drug Type Small molecule drug |
Synonyms Promethazine/sumatriptan, sumatriptan succinate/promethazine HCl, CL-H1T |
Target |
Mechanism 5-HT1D receptor agonists(Serotonin 1d (5-HT1d) receptor agonists) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhasePendingPhase 3 |
First Approval Date- |
Regulation- |
Molecular FormulaC14H21N3O2S |
InChIKeyKQKPFRSPSRPDEB-UHFFFAOYSA-N |
CAS Registry103628-46-2 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Migraine Disorders | Phase 3 | US | 16 Mar 2021 | |
Nausea and vomiting | Phase 3 | US | 15 Feb 2021 | |
Acute migraine | Phase 2 | US | 01 Feb 2019 | |
Migraine With Aura | Phase 2 | US | 01 Feb 2019 | |
Nausea | Phase 2 | US | 01 Feb 2019 | |
Pain | Phase 2 | US | 01 Feb 2019 | |
Vomiting | Phase 2 | US | 01 Feb 2019 |